Treatment of Secondary Erythema Nodosum When Potassium Iodide Has Not Resolved Tender Nodules

This protocol applies to patients with secondary erythema nodosum (EB31.1) who have completed a course of potassium iodide without achieving resolution of tender erythematous nodules on the lower extremities. It defines the structured next-line approach for this specific failure scenario.

Prior treatment — goal not achieved

The preceding line used oral potassium iodide. The intended goal — complete resolution of tender erythematous nodules on the lower extremities — was not reached, meeting the threshold to advance to this protocol.

Clinical goal

The target remains full resolution of tender erythematous nodules on the lower extremities.

Next-line approach (partial overview)

When potassium iodide has not been sufficient, the protocol moves to an alternative oral agent from a different therapeutic class — including certain antibiotic or antimalarial options. The complete regimen, selection criteria, and sequencing are contained in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-021-00592-w

Doses of 50–75 mg/day have been used with caution because of its potential side effects, including methemoglobinemia, hemolysis, agranulocytosis, and peripheral motor neuropathy.

Some patients respond to hydroxychloroquine 200 mg twice daily.

Tetracyclines, such as minocycline 100 mg twice daily and tetracycline 500 mg every 6–12 h, have been considered as an option for chronic EN.

Erythema nodosum is generally self-limited and resolves within 1–6 weeks by turning from a bright red to a yellow–brown or green-bluish discoloration, resembling bruises.

View source ↗